Suchergebnisse - "Ofran, Yishai"

PubPharm (10)

1

Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE) : part one of a randomised, phase 2, dose optimisation study

enthalten in: The Lancet. Haematology | 2023

von Pabst, T. | Papayannidis, C. | Demirkan, F. | +23

CommentIn: Lancet Haematol. 2023 Nov;10(11):e868-e870. - PMID 37914475

2

Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study

enthalten in: American journal of hematology | 2022

von Jonas, B. | DiNardo, C. | Fracchiolla, N. | +13

3

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission

enthalten in: The New England journal of medicine | 2020

von Wei, A. | Döhner, H. | Pocock, C. | +127

CommentIn: Nat Rev Clin Oncol. 2021 Mar;18(3):132. - PMID 33462426

4

Second line azacitidine for elderly or infirmed patients with acute myeloid leukemia (AML) not eligible for allogeneic hematopoietic cell transplantation-a retrospective national multicenter study

enthalten in: Annals of hematology | 2017

von Ram, R. | Gatt, M. | Merkel, D. | +5

5

Second line azacitidine for elderly or infirmed patients with acute myeloid leukemia (AML) not eligible for allogeneic hematopoietic cell transplantation—a retrospective national multicenter study

enthalten in: Annals of hematology | 2017

von Ram, R. | Gatt, M. | Merkel, D. | +5

6

Second line azacitidine for elderly or infirmed patients with acute myeloid leukemia (AML) not eligible for allogeneic hematopoietic cell transplantation—a retrospective national multicenter study

enthalten in: Annals of hematology | 2017

von Ram, R. | Gatt, M. | Merkel, D. | +5

7

Second line azacitidine for elderly or infirmed patients with acute myeloid leukemia (AML) not eligible for allogeneic hematopoietic cell transplantation—a retrospective national multicenter study

enthalten in: Annals of hematology | 2017

von Ram, R. | Gatt, M. | Merkel, D. | +5

8

Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol

enthalten in: Annals of hematology | 2016

von Mittelman, M. | Filanovsky, K. | Ofran, Y. | +10

9

Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndrome

enthalten in: Clinical lymphoma, myeloma & leukemia | 2015

von Ofran, Y. | Filanovsky, K. | Gafter-Gvili, A. | +20

CommentIn: Clin Lymphoma Myeloma Leuk. 2015 Sep;15(9):e141-2. - PMID 26257105

10

Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine : a retrospective multicenter study

enthalten in: American journal of hematology | 2013

von Merkel, D. | Filanovsky, K. | Gafter-Gvili, A. | +20

1
[1]